Pancreatic Disorders News

SAN ANTONIO — Healio will host its second Disruptive Innovators reception during the American College of Gastroenterology’s Annual Scientific Meeting (ACG 2019) on October 27, 2019, at the Grand Hyatt San Antonio.

A research team led by physician-scientists from Cedars-Sinai was awarded $10 million from the Department of Defense to study risk factors and behaviors that contribute to pancreatic diseases, according to a press release.

Volanesorsen reduced triglycerides in 77% of patients with familial chylomicronemia syndrome to less than 750 mg/dL, according to a study published in The New England Journal of Medicine.

In this guest commentary, Amrita Sethi, MD, and Uzma Siddiqui, MD, leaders of Women in Endoscopy (WIE), address the recent Twitter-storm over the low number of women matched in advanced endoscopy fellowships for the upcoming year. Tyler Berzin, MD, FASGE, pointed out that only nine of the 70 matched fellowships would be occupied by women in 2019, for a rate of just 12.9%.

May 29 is World Digestive Health Day. Created in 2003 to commemorate the 45th anniversary of the establishment of the World Gastroenterology Organisation, World Digestive Health Day aims to raise awareness and provide resources and tools for gastrointestinal diseases and disorders.

SAN DIEGO — Over the next four days, the gastroenterology community will convene in the San Diego Convention Center for Digestive Disease Week 2019, the specialty’s largest scientific conference.

Medical cannabis could be an effective adjunctive therapy for the treatment of pain associated with chronic pancreatitis, according to research published in Clinical Gastroenterology and Hepatology.

NEWARK, Del. — Pancreatic cancer is on the rise and is expected to surpass colon and rectal cancer as the third-leading cause of cancer-related death, Fedele DePalma, MD, gastroenterologist at Christiana Care Health System, said at the second annual GI Symposium.

PHILADELPHIA — Rectal indomethacin dose escalation in high-risk patients undergoing endoscopic retrograde cholangiopancreatography did not confer any benefit over the standard dose for the prevention of post-ERCP pancreatitis, according to study results presented at the American College of Gastroenterology Annual Meeting.

The FDA granted orphan drug designation to olaparib for the treatment of patients with pancreatic cancer, according to the agent’s manufacturer.